autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Jan 2017: Trial registered, NCT03014804
  2. 24 Jul 2020: Trial withdrawn, NCT03014804

The trials

NCT03014804: Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

State
Withdrawn before it started
Phase
Phase 2
People
0 taking part
Started
1 Dec 2019
Primary completion
1 Dec 2020
Arms
Group II (DCVax-L, nivolumab)
Results
None posted
  1. 9 Jan 2017: Trial registered
  2. 24 Jul 2020: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.